Vaxart (OTCMKTS:VXRT) and Oculis (NASDAQ:OCS) Critical Survey

Oculis (NASDAQ:OCS) and Vaxart (OTCMKTS:VXRT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Valuation & Earnings

This table compares Oculis and Vaxart”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45 million	458.64	-$119.44 million	($1.74)	-6.59
Vaxart	$237.26 million	0.50	$16.33 million	$0.16	3.03

Vaxart has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Oculis and Vaxart, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1	0	9	0	2.80
Vaxart	0	1	0	0	2.00

Oculis presently has a consensus price target of $38.00, indicating a potential upside of 231.30%. Given Oculis’ stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Vaxart.

Profitability

This table compares Oculis and Vaxart’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Vaxart	15.88%	53.04%	20.85%

Institutional & Insider Ownership

22.3% of Oculis shares are held by institutional investors. Comparatively, 18.0% of Vaxart shares are held by institutional investors. 2.8% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Oculis has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Summary

Vaxart beats Oculis on 9 of the 14 factors compared between the two stocks.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.